Kevin Williams
Analyst · Northcoast Research. Your line is open
Thanks, Dave. Our support and services line of revenue which represents 96% of our total revenue for the fourth quarter and fiscal year-end continues to drive our revenue growth. To break our support and services down a little bit implementation of service revenue of $14.7 million versus $17.9 million or down 18% for the quarter. As Dave said, electronic payments of $131.5 million versus $121.4 million increased 8% for the quarter. Our OutLink outsourcing division grew to $84.1 million from $69.7 million or 21% increase. Our in-house maintenance increased to $81.4 million versus $76.2 million or 7% increase, and our bundled services grew to $41.7 million from $33.4 million or 25% increase. Our total revenue grew 10% for the quarter and grew 7% if you back out the total deconversion fees of $14.9 million in the quarter and $5 million in year ago quarter. For the fiscal year total revenue grew 8% and grew 7% if you back out total deconversion fees of $37.6 million this year versus $26.9 million last year. Our total operating expenses decreased 21% for the quarter and increased 1% for the fiscal year compared to year ago period primarily to the gain on sale of Alogent, net of related expenses for a net impact of $18.5 million. Without this impact total operating expenses actually increased 12% for the quarter and 9% for the year. Increased personnel expense in R&D and G&A drove the majority of the increase for both the quarter and fiscal year. Disposal of some assets also increased the R&D expense for the quarter. Our operating margin without the impact of Alogent remained level at 27% for the quarter and 25% for the year compared to the prior year. The effective tax rate for the quarter decreased to 27.4% for the quarter from 32.1% last year. But again without the impact from Alogent the effective tax rate would have been right in line with last year at 32% for the fourth quarter. For the year, effective tax rate was 31% with the impact of Alogent and 32.4% without Alogent compared to 33.3% last year. The net tax rate without Alogent was lower this year due primarily to the reinstatement of the Research and Experimentation Credit as we got an additional half year catch-up; therefore we anticipate next year's effective tax rate to be close to 34% to 34.5%. Net income was up 39% to $84.3 million from $60.5 million a year ago which led to EPS of $1.06 which was up 42% over last year EPS of $0.75. Excluding the effects of Alogent our net income would have been $66.5 million or $60.5 million a year ago and EPS of $0.84 compared to $0.75 or 12% increase. So the fiscal year our net income was $240.9 million up 18% from $211.2 million last year which represent EPS of $3.12 up from $2.59. Excluding the effects of Alogent our net income would have been $231.4 million or up 10% from $211.2 million and EPS of $2.90 per share for the fiscal year compared to $2.59 last year or 12.1% increase. EBITDA for the year-to-date increased to $491.6 million compared to $437 million last year or a 12.5% increase. Without the effects of Alogent gain, EBITDA grew roughly 9%. Included in the total amortization disclosed in the press release, is amortization of intangibles from acquisitions, which was down to $18.4 million compared to $20 million last fiscal year. Free cash flow defined as operating cash flow less CapEx and cap software plus the proceeds of sale of assets, was $237.4 million for FY 2016 or $2.98 per share compared to $236.8 million or $2.90 per share in FY 2015. Free cash flow was impacted this year by increased capitalized software, which cap software for the quarter actually decreased approximately about $5 million sequentially compared to Q3, which -- this was also part of the increase in R&D expense and impact on operating margin in the quarter. Also we are projecting cap software to be down slightly in FY 2017 compared to FY 2016. Also impacting our cash flow was our annual maintenance billing collections were a little slower this year compared to last year by approximately $10 million at June 30, which those collections are subsequently caught up. We continue to return investment to our shareholders through dividends of $84.1 million for the year and stock buybacks of $175.7 million for the year. Our return on equity for the trailing 12-months was 25% or 23.3% after backing out the impact of Alogent. So FY 2017 initial guidance. Revenue growth will be slowed in FY 2017 as we grow over a couple of rather large headwinds. The first is obviously the sale of Alogent, which represent $28.4 million in revenue in FY 2016 or about a 2% headwind. The other is the expected significant decrease in deconversion fees in FY 2017. We anticipate these one-time deconversion fees to decrease by just under $12 million or approximately 1% headwind compared to FY 2017, which certainly is more in line with what we saw in FY 2017 or FY 2015, I'm sorry. The majority of this anticipated decrease is due specifically to two major deals that we discussed on previous earnings calls. Close to $5 million from one deal in December, in the December quarter, and $4.6 million from one in the June quarter, which is timing of that and the others in the fourth quarter was a large part of the fourth quarter $0.04 EPSD. But we do not anticipate losing any of large deals of this significance this year, which is why we're lowering the expectations. However, both of these were created by M&A activity over which we have no control. So backing these out for an apples-to-apples comparison, the base revenue would be reduced to little over $40 million to a base of $1.314 billion for FY 2016 and based on that revenue growth for FY 2017 would be somewhat in line with this year in the area of about a 7% growth. So with these headwinds right now, we anticipate actual reported revenue growth to be in the area of 4% for FY 2017. Obviously, the $19.5 million gain on disposal of business during FY 2016 must be backed out of operating expenses to arrive at a comparable operating income for comparison. Even with a loss of the large electronic payments customer, as Dave mentioned last year, that we talked about previously, this creates large headwinds on our margins. However, we do anticipate a small margin expansion, primarily in the second half of the year. So from the projected approximately 4% reported revenue growth we anticipate, operating income growth should be approximately 6% or a little better after backing out the gain compared to FY 2016 operating income. Without the headwinds of Alogent and the expected reduction deconversion fees, our operating income would have actually been projected to grow over 10% FY 2017. So our business operations remain very strong. We just have a couple of unusual items to grow over this coming year. As mentioned above, the effective tax rate for FY 2017 would be in the range of 34% to 34.5% compared to 32.4% in FY 2016, adjusting for the Alogent gain, which obviously will be a headwind on net income growth. For EPS guidance, first, you need the back out the gain on the sale of Alogent net of related cost, which was $0.22 of EPS this year, to determine a net base of $2.90 for FY 2016. The change in the effective tax rate represents approximately $0.05 EPS headwind and the anticipated decreased deconversion fees represent approximately $0.10 EPS headwind. So this is a very large headwind of approximately $0.15 EPS impact. Therefore, at this time, we expect reported EPS to grow 5% to 6% over actual reported FY 2016 after adjusting for the gain on sale of business. For FY 2017 EPS, should be in the range of $3.04 to $3.06 aided by some planned stock buyback, which was slightly lower than the current consensus estimate of $3.08. Again, our operations of business continue to be very strong. Obviously, we will update these guidance quarterly as we proceed through FY 2017. This concludes our opening comments, and we are now ready to take questions. Andrew, will you please open the call up for questions.